GlassScriptPhysician profile
Brian H Kaplan
NPI 1205015765
$11,794.41
in general payments reported to CMS, 2019-2025
34 companies · $2,763 in 2025
The $2,763 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $387 · 2021: $1,029 · 2022: $2,360 · 2023: $2,241 · 2024: $1,861 · 2025: $2,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,848 · Education: $16.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,848.22 |
| Education | $16.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,524.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,623.77 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,404.45 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,206.95 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $1,060.08 | 2021-2024 | Zeposia |
| Pfizer INC. | $516.86 | 2019-2025 | |
| Genzyme Corporation | $433.88 | 2022-2025 | |
| Celltrion USA INC. | $328.71 | 2023-2025 | Vegzelma, Yuflyma |
| Merck Sharp & Dohme LLC | $249.59 | 2019-2025 | Dificid, Prevymis |
| Pharmacosmos Therapeutics INC. | $165.89 | 2023 | Monoferric |
| Daiichi Sankyo INC. | $151.03 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $110.79 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $110.46 | 2022-2023 | Ibsrela |
| Boston Scientific Corporation | $99.63 | 2019 | |
| Braintree Laboratories, INC. | $95.23 | 2019-2024 | Sutab, Suflave |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $94.50 | 2024 | Voquezna |
| Shire North American Group INC | $85.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $83.92 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $77.74 | 2019-2022 | |
| Sandoz INC. | $47.21 | 2023 | Hyrimoz |
| Aimmune Therapeutics, INC. | $40.06 | 2025 | Zenpep |
| Redhill Biopharma INC. | $34.58 | 2020-2021 | |
| Enterra Medical, INC. | $33.49 | 2025 | |
| Fresenius Kabi USA, LLC | $28.55 | 2023 | Idacio |
| Tersera Therapeutics LLC | $23.96 | 2022 | |
| Evoke Pharma, INC. | $23.54 | 2025 | |
| Neuraxis, INC. | $21.07 | 2025 | |
| Medtronic Vascular, INC. | $19.63 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.23 | 2023 | Cyltezo |
| Shield Therapeutics INC | $18.08 | 2024 | |
| Nestle Healthcare Nutrition INC. | $15.62 | 2022 | |
| Novo Nordisk INC | $14.23 | 2022 | |
| Qol Medical, LLC | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.